Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Biomedicine (Taipei) ; 12(3): 40-47, 2022.
Article in English | MEDLINE | ID: mdl-36381193

ABSTRACT

Background: The key role of apolipoprotein C-1 (ApoC-1) is reported in breast, pancreas and lung cancer. However, no information is available on potential difference of ApoC-1 between OSCC patients and healthy individuals. This work aimed to examine the serum ApoC-1 level as well as lipid profile values between OSCC patients and healthy control groups. Material and methods: In this study, 44 blood samples from 22 OSCC patients and 22 healthy individuals were collected to determine the values of lipid profile and ApoC-1 concentration using colorimetric method and Enzyme-Linked Immunosorbent Assay (ELISA), respectively. Results: A significant decrease in serum lipid profile and ApoC-1 concentration was observed between OSCC and healthy control groups (P = 0.001). Conclusion: Our results confirm the previous findings on the significant differences of lipid profile between OSCC and controls, also show the lower serum level of ApoC-1 in OSCC as compared to the controls. Future studies would further elaborate the association of ApoC-1 with OSCC.

2.
Biomedicine (Taipei) ; 12(4): 55-62, 2022.
Article in English | MEDLINE | ID: mdl-36816175

ABSTRACT

Background: Altered acetyl CoA acetyltransferase 1 (ACAT1) expression has been reported in diverse cancers. However, the expression of ACAT1 and its prognostic value in oral squamous cell carcinoma (OSCC) has remained unexplored. Materials and methods: In this study, the expression of ACAT1 was analysed by immunohistochemistry (IHC) in 61 OSCC patients and compared between OSCC and adjacent pre-tumour tissue of 21 patients. Results: The expression of ACAT1 in OSCC tumours is heterogeneous between patients. More specifically, 52.38% of the patients show low expression of ACAT1 in both tumour and adjacent pre-tumour tissues, 9.52% of the patients show high expression of ACAT1 in both tumour and adjacent pre-tumour, 19.05% of the patients have high expression of ACAT1 in tumour tissue and low expression of ACAT1 in adjacent pre-tumour tissue and another 19.05% of the patients have low expression of ACAT1 in tumour tissue and high expression of ACAT1 in adjacent pre-tumour tissue. Conclusion: Comparison of ACAT1 expression, one of the key enzymes in the ketone body metabolic pathway, divided OSCC patients into two groups: 1) similar expression and 2) different expression of ACAT1 in tumour and adjacent pre-tumour tissue. No significant association between ACAT1 levels and overall survival was observed.

SELECTION OF CITATIONS
SEARCH DETAIL
...